Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 1;36(5):481-490.
doi: 10.1097/WCO.0000000000001198. Epub 2023 Aug 3.

Advanced brain imaging for the diagnosis of Alzheimer disease

Yi-Ting Tina Wang  1 , Pedro Rosa-Neto, Serge Gauthier
Affiliations
Review

Advanced brain imaging for the diagnosis of Alzheimer disease

Yi-Ting Tina Wang et al. Curr Opin Neurol. .

Abstract

Purpose of review: The purpose is to review the latest advances of brain imaging for the diagnosis of Alzheimer disease (AD).

Recent findings: Brain imaging techniques provide valuable and complementary information to support the diagnosis of Alzheimer disease in clinical and research settings. The recent FDA accelerated approvals of aducanumab, lecanemab and donanemab made amyloid-PET critical in helping determine the optimal window for anti-amyloid therapeutic interventions. Tau-PET, on the other hand, is considered of key importance for the tracking of disease progression and for monitoring therapeutic interventions in clinical trials. PET imaging for microglial activation, astrocyte reactivity and synaptic degeneration are still new techniques only used in the research field, and more studies are needed to validate their use in the clinical diagnosis of AD. Finally, artificial intelligence has opened new prospective in the early detection of AD using MRI modalities.

Summary: Brain imaging techniques using PET improve our understanding of the different AD-related pathologies and their relationship with each other along the course of disease. With more robust validation, machine learning and deep learning algorithms could be integrated with neuroimaging modalities to serve as valuable tools for clinicians to make early diagnosis and prognosis of AD.

PubMed Disclaimer

References

    1. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2:a006213.
    1. Zhang Y, Schuff N, Camacho M, et al. MRI markers for mild cognitive impairment: comparisons between white matter integrity and gray matter volume measurements. PLoS One 2013; 8:e66367.
    1. Wu A, Sharrett AR, Gottesman RF, et al. Association of brain magnetic resonance imaging signs with cognitive outcomes in persons with nonimpaired cognition and mild cognitive impairment. JAMA Netw Open 2019; 2:e193359.
    1. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73:294–301.
    1. Ntiri EE, Holmes MF, Forooshani PM, et al. Improved segmentation of the intracranial and ventricular volumes in populations with cerebrovascular lesions and atrophy using 3D CNNs. Neuroinformatics 2021; 19:597–618.